Provectus Biopharmaceuticals Inc PVCT:OTCQB

RT Quote | Exchange | USD
Last | 3:53 PM EST
0.071quote price arrow up+0.001 (+1.43%)
Volume
110,992
52 week range
0.03 - 0.13

...

Loading . . .

KEY STATS

  • Open0.07
  • Day High0.0725
  • Day Low0.069
  • Prev Close0.07
  • 52 Week High0.13
  • 52 Week High Date08/06/20
  • 52 Week Low0.03
  • 52 Week Low Date03/19/20
  • Market Cap28.00M
  • Shares Out394.36M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.56
  • 1 Year % Change20.75

RATIOS/PROFITABILITY

  • EPS (TTM)-0.01
  • P/E (TTM)-5.86
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-4.175M
  • ROE (MRQ)-934.31%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-81.25%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Provectus Biopharmaceuticals Inc News

There is no recent news for this security.

Latest PVCT News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic...
Edward Pershing CPA
Chairman
Dominic Rodrigues
Vice Chairman
Timothy Scott Ph.D.
President
Bruce Horowitz
Chief Operating Officer
Heather Raines
Chief Financial Officer
Eric Wachter Ph.D.
Chief Technology Officer
Address
10025 Investment Dr Ste 250
Knoxville, TN
37932-2664
United States